Treatment of patients hospitalized for psoriasis

Dermatologic Clinics

Volumn 18, Issue 3, 2000, Pages 425-435

  Prodanovich, Srdjan ^b,c   Kirsner, Robert S ^a   Richard Taylor, J ^a,c  

^a Department of Dermatology and Cutaneous Surgery ^*  (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; CYCLOSPORIN A; DITHRANOL; TACROLIMUS;

DRUG MECHANISM; HIGH RISK PATIENT; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; PSORIASIS; PUSTULAR PSORIASIS; QUALITY OF LIFE; REMISSION; REVIEW;

EID: 0033900197     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70191-1     Document Type: Article

References (122)

1. Selection of the right approach: Treatment settings
2. Proliferative responses of peripheral blood mononuclear cells from psoriatic patients to T lymphocyte-stimulating cytokines (IL-2, IL-3, IL-4, and granulocyte-macrophage colony-stimulating factor) and OK-432
3. Polynuclear aromatic compounds: Part 4. Bitumens, coal tars and derived products, shale oil and soots
4. Anthralin: Historical and current perspectives
5. Group A streptococcal antigen-specific T lymphocytes in guttate psoriatic lesions
6. Altered cell-mediated immunity to group A hemolytic streptococcal antigens in chronic plaque psoriasis
7. Generalized pustular psoriasis: A clinical and epidemiological study of 104 cases
8. Corticosteroids and pustular psoriasis
9. Pustular psoriasis
10. Generalized pustular psoriasis
11. Combination therapy for psoriasis
12. Association between psoriasis and the alpha-1-antitrypsin deficiency gene Z
13. Dioxyanthranol 1-8 as a substitute for chrysarobin
14. Experimenteller und klinischer Nachweis der antiproliferativen Wirkung einer hochgereinigten Steinkohlenteer-Fraction in einer speziellen Gelgrundlage
15. Correlation of anti-streptolysin-O titer to HLA 13 in psoriasis
16. White paper on hospitalization for psoriasis care
17. The prevalence of psoriasis in Denmark
18. Pregnancy and the menstrual cycle
19. Metabolic and ultrastructural studies in patients with pustular psoriasis (von Zumbusch)
20. HLA B13, B17, B37 and Cw6 in psoriasis vulgaris: Association with the age of onset
21. Clinical and morphological aspects of the topical treatment of psoriasis
22. A topical treatment program for psoriasis with low anthralin concentrations
23. Onset of psoriasis at age 108
24. Psoriasis
25. Ingram method of treating psoriasis
26. Effects of cyclosporine on immunologic mechanisms in psoriasis
27. Generalized pustular psoriasis (von Zumbusch) with episodic hypocalcemia
28. An allelic association between type I psoriasis and a polymorphism in the interleukin one receptor antagonist gene
29. Photosensitivity due to pitch
30. Psoriasis: Improvement during and worsening after pregnancy
31. Papulosquamous disorders associated with human immunodeficiency virus infection
32. Acquired immunodeficiency syndrome - Associated psoriasis and Reiter's syndrome
33. Efficacy and pharmacokinetics of two formulations of cyclosporine A in psoriasis patients
34. A double-blind evaluation of topical capsaicin in pruritic psoriasis
35. Pustulosis palmaris et plantaris: A follow-up study of a ten-year material
36. Response to injury of skin involved and uninvolved with psoriasis and its relation to disease activity
37. The Koebner response in psoriasis
38. Hospital treatment of psoriasis
39. Impetigo herpetiformis
40. Psoriasis: An index of disability
41. Topical antipsoriatic agents and epidermal mitosis in man
42. Direct binding of secreted T cell receptor beta chain to superantigen associated with class II major histocompatibility complex protein
43. Papulosquamous eruptions and exfoliative dermatitis
44. The effect of coal tar distillate, cadmium sulphide, ichthyol sodium and omadine MDS on the epidermis of the guinea pig
45. Treatment of psoriasis
46. Treatment of psoriasis: Continued observations on the use of crude coal tar and ultraviolet light
47. Response of psoriasis to a lymphocyte-selective toxin (DAB3891L-2) suggests a primary immune, but not keratinocyte, pathogenic basis
48. Recent advances in the treatment of psoriasis
49. The antipsoriatic drug, anthralin, inhibits protein kinase C - Implications for its mechanism of action
50. The chemistry, pharmacology, and use of anthralin in the treatment of psoriasis
51. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris
52. HLA and psoriasis
53. A case of AIDS manifesting pruritic popular eruptions and psoriasiform lesions: An immunohistochemical study of the lesional dermal infiltrates
54. The approach to psoriasis
55. The mode of inheritance of psoriasis: Evidence for a major gene as well as a multifactorial component and its implication for genetic counseling
56. Effects of anthralin and analogues on growth and (3H) thymidine incorporation in human skin fibroblasts
57. Tacrolimus (FK 506) - A new therapeutic agent for severe recalcitrant psoriasis
58. AIDS exacerbates psoriasis
59. Clinical and histological study of coal tar phototoxyicity in humans
60. Effects of antipsoriasis drugs and metabolic inhibitors on the growth of epidermal cells in culture
61. The bacteriology of normal skin
62. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment
63. Histocompatibility antigens: A laboratory and epidemiologic tool
64. HLA-antigen in psoriasis
65. A perspective of psoriasis as an aberration in skin modified to expression by the inflammatory/repair system
66. Trigger factors in psoriasis
67. Methotrexate in childhood psoriasis
68. Superantigen implicated in dependence of HIV-1 replication in T cells on TCR V beta expression
69. The atrophogenic effect of crude tar on human epidermis
70. Acquired immunodeficiency syndrome (AIDS) can exacerbate psoriasis
71. Anthralin
72. The role of superantigens in human disease: Therapeutic implications for the treatment of skin diseases
73. Staphylacoccus aureus in lesions of atopic dermatitis
74. Combination therapy and the use of an initial dose of intramuscular methotrexate in patients hospitalized for psoriasis
75. Dermatitis herpetiformis presenting as impetigo herpetiformis
76. Severe osteolytic arthritis mutilans in pustular psoriasis
77. Dithranol
78. Cross-reactivity between streptococcal M surface antigen and human skin
79. Successful treatment of generalized pustular psoriasis (von Zumbasch) by systemic antibiotics controlled by blood culture
80. Physico-chemical properties and stability of anthralin in model systems and human skin
81. Class II MHC molecules are specific receptors for staphylococcus enterotoxin A
82. Anthralin-corticosteroid combination therapy in the treatment of chronic plaque psoriasis
83. Controlled study of PUVA and adjunctive topical therapy in the management of psoriasis
84. CD4 antibody treatment of severe psoriasis
85. The role of microorganisms in psoriasis
86. Palmoplantar pustulosis and smoking
87. Generalized pustular psoriasis: Induction by topical use of coal tar
88. Epidermal rupture is the initiating factor for the Koebner response in psoriasis
89. Chimaeric CD4 monoclonal antibody m treatment of generalised pustular psoriasis
90. Ingrain method: The precursor of photo-chemotherapy
91. Antirespiratory and antiproliferative activity of anthralin in cultured human keratinocytes
92. Research needs in 11 major areas in dermatology
93. Human immunodeficiency virus associated psoriasis, psoriatic arthritis, and Reiter's syndrome: A disease continuum?
94. Histocompatibility (HL-A) antigens associated with psoriasis
95. Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis
96. Familial juvenile onset psoriasis is associated with the human leukocyte antigen (HLA) class I side of the extended haplotype Cw6-B57-DRB1*0701-DQA1*0201-DQB1*0303: A population- and family-based study
97. Relapse rate of psoriasis worsened by adding steroids to a dithranol regime
98. Anthralin in psoriasis
99. Pustular and erythrodermic psoriasis
100. Tars and anthralins
101. Interferon gamma-treated keratinocytes activate T cells in the presence of superantigens: Involvement of major histocompatibility complex class II molecules
102. HLA in psoriasis vulgaris and in pustular psoriasis - Population and family studies
103. Trigerring factors
104. Tarphototoxicity and phototherapy for psoriasis
105. The role of streptococcal infection in the initiation of guttate psoriasis
106. Immunointervention in psoriasis with anti-CD4 antibodies
107. Pustulosis palmaris and plantaris
108. Cignolin als Heilmittel der Psoriasis
109. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens?
110. Psoriasis and pustuloses: Exanthem
111. HLA-antigens in persistent palmoplantar pustulosis and its relationship to psoriasis
112. Oligaemia, renal failure, and jaundice associated with acute pustular psoriasis
113. Localization of transforming growth factor alpha RNA and protein in the skin of psoriatic patients receiving therapy
114. Disturbance of HLA-antigen frequency in psoriasis
115. Palmoplantar pustular psoriasis provoked by lithium therapy
116. Experimental contribution to the dithranol-brown problem
117. An open prospective clinical trial with systemic ranitidine in the treatment of psoriasis
118. Scale prophylaxis: A new antiparakeratotic assay
119. Tonsil and pustulosis palmaris et plantaris
120. Generalized pustular psoriasis: A review of 63 cases